Профилактика инсульта у пациента с фибрилляцией предсердий и сопутствующими заболеваниями
https://doi.org/10.26442/2075-082X_2018.2.55-59
Аннотация
Об авторах
О. Д. ОстроумоваРоссия
Н. Ю. Воеводина
Россия
Т. Ф. Гусева
Россия
Е. Е. Павлеева
Россия
Г. Ф. Пиксина
Россия
И. В. Голобородова
Россия
Список литературы
1. O’Donnell M.J, Xavier D, Liu L. et al; INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010: 376; 112-23. DOI: 10.1016/S0140-6736(10)60834-3
2. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Hypertens J 2013; 31: 1281-357. DOI: 10.1093/eurheartj/eht151
3. Диагностика и лечение артериальной гипертонии: клинические рекомендации. Кардиологический вестн. 2015; X (1): 3-30.
4. Kirchhof P, Benussi S, Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38): 2893-962. DOI: 10.1093/ejcts/ezw313
5. Stewart S, Hart C.L, Hole D.J, McMurray J.J. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516-21. DOI: 10.1136/heart.86.5.516
6. Go A.S, Hylek E.M, Phillips K.A et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-5.
7. Miyasaka Y, Barnes M.E, Gersh B.J et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-125. DOI: 10.1161/CIRCULATIONAHA.105.595140
8. Heeringa J, van der Kuip D.A, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949-53. DOI: 10.1093/eurheartj/ehi825
9. Naccarelli G.V, Varker H, Lin J, Schulman K.L. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009; 104: 1534-9. DOI: 10.1016/j.amjcard.2009.07.022
10. Lloyd-Jones D.M, Wang T.J, Leip E.P et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110: 1042-6. DOI: 10.1161/01.CIR.0000140263.20897.42
11. Рубаненко О.А. Коморбидная патология у пациентов с фибрилляцией предсердий. Известия Самарского научного центра РАН. 2015; 17 (2): 367-70
12. Lip G.Y, Laroche C, Dan G.A. et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014; 16 (3): 308-19. DOI: 10.1093/europace/eut373
13. Dorian P, Guerra P.G, Kerr C.R et al. Validation of a new simple scale to measure symptoms in atrial fibrillation: the Canadian Cardiovascular Society Severity in Atrial Fibrillation scale. Circ Arrhythm Electrophysiol 2009; 2: 218-24. DOI: 10.1161/CIRCEP.108.812347
14. Cho J.R, Angiolillo D.J. Percutaneous coronary intervention and atrial fibrillation: The triple therapy dilemma. J Thromb Thrombolysis 2015; 39: 203-8. DOI: 10.1007/s11239-014-1132-z
15. Valgimigli M, Bueno H, Byrne R.A et al; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39 (3): 213-60. DOI: 10.1093/eurheartj/ehx419
16. Bahit M.C, Lopes R.D, Wojdyla D.M et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trial. Int J Cardiol 2013; 170: 215-20. DOI: 10.1016/j.ijcard.2013.10.062
17. Benjamin E.J, Levy D, Vaziri S.M et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271 (11): 840-4.
18. Furberg C, Psaty B, Monolio T et al. The CHS Collaborative Research Group Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74 (3): 236-41. DOI: https://doi.org/10.1016/0002-9149(94)90363-8
19. Cleland J.G, Chattopadhyay S, Khand A et al. Prevalence and incidence of arrhythmias and sudden death in heart failure. Heart Fail Rev 2002; 7 (3): 229-42.
20. Dries D, Exner D, Gersh B.J et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Am Coll Cardiol 1998; 32 (3): 695-703. https://doi.org/10.1016/S0735-1097(98)00297-6
21. Cleland J.G.F, Swedberg K, Follath F et al, for the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Euro Heart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24: 442-63.
22. McMurray J.J.V, Ezekowitz J.A, Lewis B.S. et al; ARISTOTLE Committees and Investigators.et al. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation insights from the ARISTOTLE trial. Circ Heart Fail 2013; 6 (3): 451-60. DOI: 10.1161/CIRCHEARTFAILURE.112.000143
23. Ezekowitz J.A, Lewis B.S, Lopes R.D et al. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother 2015; 1 (2): 86-94. DOI: 10.1093/ehjcvp/pvu024
24. Grand’Maison A, Charest AF, Geerts WH. Anticoagulant use in patients with chronic renal impairment. Am J Cardiovasc Drugs 2005; 5 (5): 291-305.
25. Go A.S, Fang M.C, Udaltsova N et al; ATRIA Study Investigators.et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009; 119 (10): 1363-9. DOI: 10.1161/CIRCULATIONAHA.108.816082
26. Herzog C.A, Asinger R.W, Berger A.K et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80 (6): 572-86. DOI: 10.1038/ki.2011.223
27. Hohnloser S.H, Hijazi Z, Thomas L et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33 (22): 2821-830. DOI: 10.1093/eurheartj/ehs274
28. Soliman E.Z, Prineas R.J, Go A.S et al; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010; 159 (6): 1102-7. DOI: 10.1016/j.ahj.2010.03.027
29. Hijazi Z, Hohnloser S.H, Andersson U et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol 2016; 1 (4): 451-60. DOI: 10.1001/jamacardio.2016.1170
30. Dhamoon M.S, Tai W, Boden-Albala B et al. Risk of myocardial infarction or vascular death after first ischemic stroke: The Northern Manhattan Study. Stroke 2007; 38: 1752-8. DOI: 10.1161/STROKEAHA.106.480988
31. Carter A.M, Catto A.J, Mansfield M.W et al. Predictive variables for mortality after acute ischemic stroke. Stroke 2007; 38: 1873-80. DOI: 10.1161/STROKEAHA.106.474569
32. Weimar Ch, Benemann J, Michalski D et al; German Stroke Study Collaboration. Prediction of recurrent stroke and vascular death in patients with transient ischemic attack or nondisabling stroke. Stroke 2010; 41: 487-93. DOI: 10.1161/STROKEAHA.109.562157
33. Sacco R.L, Adams R, Albers G et al; American Heart Association; American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37: 577-617. DOI: 10.1161/01.STR.0000199147.30016.74
34. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis 2008; 25: 457-507. DOI: 10.1159/000131083
35. Furie K.L, Kasner S.E, Adams R.J et al; American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2011; 42: 227-76. DOI: 10.1161/STR.0b013e3181f7d043
36. Easton J.D, Lopes R.D, Bahit M.C et al; ARISTOTLE Committees and Investigators. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012; 11 (6): 503-11. DOI: 10.1016/S1474-4422(12)70092-3
37. Lopes R.D, Shah B.R, Olson D.M et al. Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: Results from the AVAIL registry. Stroke 2011; 42 (12): 3477-83. DOI: 10.1161/STROKEAHA.111.625392
38. Go A.S, Hylek E.M, Borowsky L.H et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999; 131 (12): 927-34.
Рецензия
Для цитирования:
Остроумова О.Д., Воеводина Н.Ю., Гусева Т.Ф., Павлеева Е.Е., Пиксина Г.Ф., Голобородова И.В. Профилактика инсульта у пациента с фибрилляцией предсердий и сопутствующими заболеваниями. Системные гипертензии. 2018;15(2):55-59. https://doi.org/10.26442/2075-082X_2018.2.55-59
For citation:
Ostroumova O.D., Voevodina N.Yu., Guseva T.F., Pavleeva E.E., Piksina G.F., Goloborodova I.V. Stroke prevention in patients with atrial fibrillation and comorbidities. Systemic Hypertension. 2018;15(2):55-59. https://doi.org/10.26442/2075-082X_2018.2.55-59
Послать статью по эл. почте 